Carmelo Rizzari

Monza, IT

Clinical Trials:Currently Recruiting for 1 Trial

Expertise in

conditions

Monza, IT

Overview

Carmelo Rizzari practices in Monza, Italy. Mr. Rizzari is highly rated in 12 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Hemophagocytic Lymphohistiocytosis, Non-Langerhans-Cell Histiocytosis, and Bone Marrow Transplant.

His clinical research consists of co-authoring 132 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Monza, Italy

Other Locations

Milan, 20126, Italy

San Gerardo, Italy

Turin, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Enrollment Status: Recruiting

Publish Date: January 16, 2024

Intervention Type: Drug, Radiation

Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon

Study Phase: Phase 2/Phase 3

An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis

Enrollment Status: Completed

Publish Date: March 12, 2024

Intervention Type: Drug

Study Drug: Emapalumab

Study Phase: Phase 3

A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis

Enrollment Status: Completed

Publish Date: February 21, 2023

Intervention Type: Biological

Study Phase: Phase 2/Phase 3

A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody

Enrollment Status: Completed

Publish Date: June 28, 2022

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

View 3 Less Clinical Trials

132 Total Publications

"Per aspera ad astra": the transformative contribution of glucarpidase to the improved management of delayed methotrexate elimination after high-dose therapy.

Journal: Expert review of hematology

Published: March 10, 2026

View All 132 Publications

Frequently Asked Questions about Carmelo Rizzari

Is Carmelo Rizzari a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Carmelo Rizzari is classified as an Elite expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Carmelo Rizzari participate in research or clinical trials?

Yes. Carmelo Rizzari has published 132 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Carmelo Rizzari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rizzari's expertise for a condition

ConditionClose